A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

Stopped early · Not applicable

Conditions studied: Bladder Cancer, Genitourinary Cancer, Prostate Cancer

In brief

The goal of this clinical research study is to evaluate how well ferumoxtran-10, a new Magnetic Resonance Imaging (MRI) contrast agent, can detect cancer in the pelvic lymph nodes or malignant pelvic lymph nodes.

Key facts

Study ID
NCT00147238
Run by
M.D. Anderson Cancer Center
People needed
10
Starts
2005-07-01
Expected to finish
2007-01-01
Last updated by the study team
2012-08-07

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.